These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 22623231)

  • 21. Cytochrome P450 2C19 polymorphism and clopidogrel after MI.
    Miao J; Liu R; Li Z
    Lancet; 2009 Apr; 373(9670):1171-2; author reply 1172-3. PubMed ID: 19345824
    [No Abstract]   [Full Text] [Related]  

  • 22. Relation of body mass index to high on-treatment platelet reactivity and of failed clopidogrel dose adjustment according to platelet reactivity monitoring in patients undergoing percutaneous coronary intervention.
    Bonello-Palot N; Armero S; Paganelli F; Mancini J; De Labriolle A; Bonello C; Lévy N; Maillard L; Barragan P; Dignat-George F; Camoin-Jau L; Bonello L
    Am J Cardiol; 2009 Dec; 104(11):1511-5. PubMed ID: 19932784
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Determination of cut-off levels for on-clopidogrel platelet aggregation based on functional CYP2C19 gene variants in patients undergoing elective percutaneous coronary intervention.
    Ono T; Kaikita K; Hokimoto S; Iwashita S; Yamamoto K; Miyazaki Y; Horio E; Sato K; Tsujita K; Abe T; Deguchi M; Tayama S; Sumida H; Sugiyama S; Yamabe H; Nakamura S; Nakagawa K; Ogawa H
    Thromb Res; 2011 Dec; 128(6):e130-6. PubMed ID: 21862109
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current evidence for genetic testing in clopidogrel-treated patients undergoing coronary stenting.
    Sibbing D; Bernlochner I; Kastrati A; Paré G; Eikelboom JW
    Circ Cardiovasc Interv; 2011 Oct; 4(5):505-13; discussion 513. PubMed ID: 22010189
    [No Abstract]   [Full Text] [Related]  

  • 25. CYP2C19 genotype and outcomes of clopidogrel treatment.
    Siasos G; Tousoulis D; Stefanadis C
    N Engl J Med; 2011 Feb; 364(5):481-2. PubMed ID: 21288101
    [No Abstract]   [Full Text] [Related]  

  • 26. Platelet inhibitors: update on clopidogrel (Plavix) and the recently approved prasugrel (Effient).
    Wynn RL
    Gen Dent; 2010; 58(1):7-9. PubMed ID: 20129886
    [No Abstract]   [Full Text] [Related]  

  • 27. Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease.
    Viviani Anselmi C; Briguori C; Roncarati R; Papa L; Visconti G; Focaccio A; De Micco F; Latronico MV; Pagnotta P; Condorelli G
    JACC Cardiovasc Interv; 2013 Nov; 6(11):1166-75. PubMed ID: 24262617
    [TBL] [Abstract][Full Text] [Related]  

  • 28. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting.
    Sibbing D; Koch W; Massberg S; Byrne RA; Mehilli J; Schulz S; Mayer K; Bernlochner I; Schömig A; Kastrati A
    Eur Heart J; 2011 Jul; 32(13):1605-13. PubMed ID: 21527445
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factors associated with clopidogrel nonresponsiveness.
    Momary KM; Dorsch MP
    Future Cardiol; 2010 Mar; 6(2):195-210. PubMed ID: 20230261
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of the proton pump inhibitors and CYP2C19*2 polymorphism on platelet response to clopidogrel as assessed by four platelet function assays.
    Tsantes AE; Ikonomidis I; Papadakis I; Bonovas S; Gialeraki A; Kottaridi C; Kyriakou E; Kokori S; Douramani P; Kopterides P; Karakitsos P; Lekakis J; Kapsimali V
    Thromb Res; 2013 Aug; 132(2):e105-11. PubMed ID: 23830212
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Omeprazole: a possible new candidate influencing the antiplatelet effect of clopidogrel.
    Gurbel PA; Lau WC; Tantry US
    J Am Coll Cardiol; 2008 Jan; 51(3):261-3. PubMed ID: 18206733
    [No Abstract]   [Full Text] [Related]  

  • 32. Association of genetic variants in CYP2C19 and adverse clinical outcomes after treatment with clopidogrel: an updated meta-analysis.
    Liu YP; Hao PP; Zhang MX; Zhang C; Gao F; Zhang Y; Chen YG
    Thromb Res; 2011 Dec; 128(6):593-4. PubMed ID: 21794898
    [No Abstract]   [Full Text] [Related]  

  • 33. CYP2C19 and ABCB1 genes and individualized treatment with clopidogrel.
    Peters BJ; Harmsze AM; ten Berg JM; Maitland-van der Zee AH; Tjoeng MM; de Boer A; Deneer VH
    Pharmacogenomics; 2011 Feb; 12(2):141-4. PubMed ID: 21332306
    [No Abstract]   [Full Text] [Related]  

  • 34. CYP2C19 genotype and outcomes of clopidogrel treatment.
    Geisler T; Bigalke B; Schwab M
    N Engl J Med; 2011 Feb; 364(5):481; author reply 482. PubMed ID: 21288102
    [No Abstract]   [Full Text] [Related]  

  • 35. Prevalence of CYP2C19 variant alleles and pharmacodynamic variability of aspirin and clopidogrel in Native Americans.
    Oestreich JH; Best LG; Dobesh PP
    Am Heart J; 2014 Mar; 167(3):413-8. PubMed ID: 24576527
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study.
    Gurbel PA; Bliden KP; Logan DK; Kereiakes DJ; Lasseter KC; White A; Angiolillo DJ; Nolin TD; Maa JF; Bailey WL; Jakubowski JA; Ojeh CK; Jeong YH; Tantry US; Baker BA
    J Am Coll Cardiol; 2013 Aug; 62(6):505-12. PubMed ID: 23602770
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.
    Trenk D; Hochholzer W; Fromm MF; Chialda LE; Pahl A; Valina CM; Stratz C; Schmiebusch P; Bestehorn HP; Büttner HJ; Neumann FJ
    J Am Coll Cardiol; 2008 May; 51(20):1925-34. PubMed ID: 18482659
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic variability in response to clopidogrel therapy: clinical implications.
    Huber K
    Eur Heart J; 2010 Dec; 31(24):2974-6. PubMed ID: 20846994
    [No Abstract]   [Full Text] [Related]  

  • 39. [Relationships of blood stasis syndrome, CYP2C19 gene polymorphism with clopidogrel resistance and post-PCI prognosis].
    Chen H; Yan W; Wu XY
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2010 Dec; 30(12):1245-9. PubMed ID: 21302482
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [A current problem for regulators. Clopidogrel and pharmacokinetics].
    Zündorf I; Dingermann T
    Pharm Unserer Zeit; 2009; 38(4):360-7. PubMed ID: 19572363
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.